Garland Jason K sold $80K of RGEN
Garland Jason K (CFO) sold 530 shares of REPLIGEN CORP (RGEN) at $150.00 on 2026-07-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale details (530 shares at $150, total $79,500) by the CFO on 2026-07-16, filed on 2026-07-17, under a 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but the disclosure lacks any fundamental catalyst (no guidance, deal, or regulatory update).
What to watch
Insider sales can be driven by diversification or tax planning; the article provides no context on total holdings, option exercises, or other concurrent insider activity.
Background
The article is a SEC Form 4 insider transaction disclosure for Repligen Corp (RGEN).
Ticker impact
Repligen CFO Garland Jason K filed a Form 4 open-market sale of 530 shares at $150 on 2026-07-16 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited and short-lived.
The filing is a routine 10b5-1 planned open-market sale with modest size ($79.5k) and no accompanying operational or guidance change in the text.
Market effects
No sector read-through is provided; this appears company-specific and routine.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not signal reduced confidence and could be ignored by most traders.
Key entities
- issuerREPLIGEN CORP
Company whose CFO insider sale is disclosed via SEC Form 4.
- insiderGarland Jason K
CFO who executed the open-market sale under a 10b5-1 plan.
